Showing posts with label White Blood Cells. Show all posts
Showing posts with label White Blood Cells. Show all posts

Monday, July 18, 2016

Supportive Treatment of Multiple Myeloma



Supportive Treatment of Multiple Myeloma


  • Supportive treatment is the treatment that aim to treat the signs & symptoms or reduce them; it is not aim to treat the disease itself.

Renal Impairment :-


  • Rehydrate.
  • Treat the underlying cause (e.g. hypercalcemia, hyperuricemia).
  • Dialysis.
  • Drink at least 3 Liter of fluid daily (all multiple myeloma cases).


Bone disease and hypercalcemia :-


  • Bisphosphonates (such as pamidronate, clodronate or zoledronic acid) reduce the progression of bone disease.
  • Rehydration with isotonic saline, a diuretic and corticosteroids followed by a biphosphonate (to treat acute hypercalcemia).


Compression paraplegia :-


  • Use decompression laminectomy or irradiation. 
  • Also corticosteroid therapy may help.


Anemia :-


  • Erythropoietin.
  • Transfusion.


Bleeding (Bleeding caused by paraprotein interference with coagulation and hyperviscosity syndrome) :-


  • May be treated by repeated plasmapheresis.


Infections :-


  • Must treated rapidly.
  • Prophylactic infusions of immunoglobulin concentrates together with oral broad - spectrum antibiotics and antifungal agents may be needed for recurrent infections.

Sunday, July 17, 2016

Multiple Myeloma: An Overview




Multiple Myeloma: An Overview


plasma cells in multiple myeloma http://hematology-lectures.blogspot.com/


Definition:-

  • Multiple myeloma (MM) is a malignant bone marrow–based, plasma cell neoplasm associated with abnormal protein production.
  • Multiple myeloma also called myelomatosis.
Epidemiology:-
  • 1~2% of all types of malignant diseases
  • ~10% of hematological malignancies.
  • 15% of lymphoid malignancies.
  • ~ 50 cases per million.
  • Twice common in black than white people.
  • Slightly more common in males than in females.
  • 98% of cases occur over the age of 40 years with a peak incidence in the 7th decade.
Etiology (Causes):-

- Exact cause is unknown, but the following are suspects:
  • Radiation.
  • Viral infections.
  • Toxins.
  • Chemicals.
  • Chromosomal abnormalities ( 8 % - 35 % of MM patients ).
- MM patients with chromosomal damage have a worse prognosis, a higher rate of disease acceleration, and decreased survival. 
Clinical Signs & Symptoms:-
  • Fatigue: caused by anemia
  • Excessive thirst and urination: caused by excess calcium.
  • Nausea: caused by excess calcium.
  • Bone pain in back and ribs: caused by plasma cell acceleration.
  • Bone fractures: caused by calcium leeching from bones into circulation.
  • Unexpected infections: caused by compromised immunity.
  • Weakness and numbness in the legs: caused by vertebrae compression. 
  • Renal insufficiency.(Myeloma kidney).
  • Hypercalcemia.
  • Amyloidosis (in 5% of cases).
  • Weight loss & night sweats (in advanced cases).
  • Abnormal bleeding tendency: myeloma protein may interfere with platelet function and coagulation factors
  • Thrombocytopenia (in advanced cases).
Laboratory Findings:-
  • Anemia (2/3 of cases). ( Normocytic normochromic anemia ).
  • Leukopenia (1/3 of cases).
  • Thrombocytopenia.
  • ESR > 100 mm/hr.
  • Blood film shows rouleaux with a bluish background staining.
  • Bone marrow shows >10% plasma cells.
  • ↑ Total protein.
  • ↑ Uric Acid.
  • ↑ LDH.
  • Hypercalcemia.
  • Protein electrophoresis (monoclonal spike in the gamma region).
  • Bence-Jones protein (immunoglobulin light chain) in urine. (in some cases).
  • Serum β2 microglobulin (β2M) often raised and higher levels correlate with worse prognosis.
Radiology:-

X-rays, CT scan, MRI or PET.

Prognostic Data:-

Prognostic data include:-
  • Hb.
  • β2M.
  • Creatinine.
  • Albumin. &
  • Extent of skeletal disease.
Treatment:-
  • Chemotherapy.
  • Supportive.
  • Radiation.
  • Transplantation (bone marrow; stem cell).
Prognosis:-
 
  • The prognosis of MM is poor.
  • Median survival of only 6 months without therapy.
  • The median survival can be increased to 3 years with chemotherapy.
  • Increased survival has been reported with autologous bone marrow & peripheral blood stem cell transplants.
  • Infection is a major cause of death.



Friday, December 4, 2015

Multiple Myeloma





     Multiple myeloma (myelomatosis) is a neoplastic disease characterized by plasma cell  accumulation in the bone marrow, the presence of monoclonal protein in the serum and/or urine and, in symptomatic patients, related tissue damage.